Nothing Special   »   [go: up one dir, main page]

ES2098023T3 - Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen. - Google Patents

Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2098023T3
ES2098023T3 ES93901791T ES93901791T ES2098023T3 ES 2098023 T3 ES2098023 T3 ES 2098023T3 ES 93901791 T ES93901791 T ES 93901791T ES 93901791 T ES93901791 T ES 93901791T ES 2098023 T3 ES2098023 T3 ES 2098023T3
Authority
ES
Spain
Prior art keywords
pct
guanidinic
pharmaceutical compositions
compositions containing
structure compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93901791T
Other languages
English (en)
Inventor
Claude Thal
Catherine Quirosa-Guillou
Pierre Potier
Dolor Renko
Jean-Pierre Zanetta
Marie-Madeleine Portier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2098023T3 publication Critical patent/ES2098023T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION TIENE POR OBJETO, NUEVOS COMPUESTOS DE ESTRUCTURA GUANIDICA DE FORMULA (I), EN LA CUAL R1 ES UN RADICAL ISOPROPILENO, BENCILO EVENTUALMENTE SUSTITUIDO POR UNO O VARIOS RADICALES (C1-C4) ALCOXI O UN RADICAL (A); R2, R3 Y R4 SON EL ATOMO DE HIDROGENO O CONJUNTO QUE PUEDE FORMAR UN CICLO IMIDAZOL, PIRIMIDINA, DIHIDROPIRIMIDINA, PIROMIDINIO. ESTOS COMPUESTOS SON NOTABLEMENTE UTILES PARA REGENERAR EL AXON DE LAS NEURONAS EN CIERTAS ENFERMEDADES COMO LAS NEUROPATIAS Y MIOPATIAS.
ES93901791T 1991-11-22 1992-11-20 Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2098023T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR919114414A FR2684103B1 (fr) 1991-11-22 1991-11-22 Nouveaux composes a structure guanidique et composition pharmaceutique les contenant.

Publications (1)

Publication Number Publication Date
ES2098023T3 true ES2098023T3 (es) 1997-04-16

Family

ID=9419217

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93901791T Expired - Lifetime ES2098023T3 (es) 1991-11-22 1992-11-20 Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.

Country Status (10)

Country Link
US (2) US5480884A (es)
EP (1) EP0572635B1 (es)
JP (1) JPH06505027A (es)
AT (1) ATE146780T1 (es)
CA (1) CA2101058A1 (es)
DE (1) DE69216221T2 (es)
DK (1) DK0572635T3 (es)
ES (1) ES2098023T3 (es)
FR (1) FR2684103B1 (es)
WO (1) WO1993010102A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
CA2811990C (en) * 2010-08-23 2023-03-21 Dean Y. Maeda Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2145011A (en) * 1935-02-23 1939-01-24 Soc Of Chemical Ind Process for matting textiles
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4814007A (en) * 1986-01-16 1989-03-21 Henkel Corporation Recovery of precious metals
US4772609A (en) * 1986-06-26 1988-09-20 Harbor Branch Oceanographic Institution, Inc. Antiviral guanidine derivatives and compositions therefor
IT1232783B (it) * 1989-09-04 1992-03-05 Sclavo Spa Metodo per l'alchilazione di gruppi guanidinici
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents

Also Published As

Publication number Publication date
ATE146780T1 (de) 1997-01-15
DK0572635T3 (da) 1997-06-16
FR2684103A1 (fr) 1993-05-28
JPH06505027A (ja) 1994-06-09
CA2101058A1 (fr) 1993-05-23
EP0572635A4 (fr) 1993-09-17
WO1993010102A1 (fr) 1993-05-27
US5719187A (en) 1998-02-17
DE69216221T2 (de) 1997-05-28
FR2684103B1 (fr) 1994-09-02
EP0572635B1 (fr) 1996-12-27
EP0572635A1 (fr) 1993-12-08
DE69216221D1 (de) 1997-02-06
US5480884A (en) 1996-01-02

Similar Documents

Publication Publication Date Title
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
ES2128307T3 (es) Derivados de 1,4,7,10-tetraaza-ciclododecano monosustituidos en n, procedimiento para su preparacion y agentes farmaceuticos que los contienen.
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
DE59009351D1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
DE69232854D1 (de) Bizyklische fibrinogenantagonisten
NO921835D0 (no) Fremgangsmaate for fremstilling av amidinofenylalaninderivat samt anvendelse derav
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
IL110151A0 (en) Amide and urea derivatives and pharmaceutical compositions containing the same
ES2081120T3 (es) Procedimiento para la preparacion de derivados de la bacatina iii y la desacetil-10 bacatina iii.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE73790T1 (de) Amino 5,6,7,8tetrahydronaphtho(2,3b>furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
MX9400253A (es) Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
GB9314758D0 (en) Heterocyclic derivatives
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2111871T3 (es) Nuevos derivados de aminoacidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
ES2182090T3 (es) Nuevos derivados de pirrol.
YU140491A (sh) 6-supstituisani-tetrahidrobenz(c,d) indoli
ATE100102T1 (de) Substituierte derivate von 20,21dinoreburnamenin, verfahren zur herstellung und so hergestellte zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.
ES2091570T3 (es) Nuevos derivados peptidicos antagonistas de la bradiquidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE3764918D1 (de) 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 572635

Country of ref document: ES